Journal ArticleOPEN ACCESS

Diabetes drug pioglitazone (Actos): risk of fracture

  • Meymeh R
  • Wooltorton E
Canadian Medical Association Journal (2007) 177(7) 723-724
DOI: 10.1503/cmaj.071177
N/ACitations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Reason for posting: Pioglitazone is an oral hypoglycemic agent widely used as monotherapy or combination therapy for type 2 diabetes mellitus. However, a recent analysis by the drug's manufacturer of several unpublished clinical trials in the company's database revealed an increased risk of bone

Cite

CITATION STYLE

APA

Meymeh, R. H., & Wooltorton, E. (2007). Diabetes drug pioglitazone (Actos): risk of fracture. Canadian Medical Association Journal, 177(7), 723–724. https://doi.org/10.1503/cmaj.071177

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free